Highlights Amphastar Pharmaceuticals, Inc.

Equities

AMPH

US03209R1032

Market Closed - Nasdaq Other stock markets 01:30:00 18/06/2024 am IST			5-day change	1st Jan Change
40.54 ^USD	+0.12%		-2.64%	-34.45%

04/06	Amphastar Pharmaceuticals, Inc. Approves the Appointment of Howard Lee as Director	CI
04/06	Amphastar Pharmaceuticals' Board Approves $50 Million Increase to Share Buyback Plan	MT

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Amphastar Pharmaceuticals' Board Approves $50 Million Increase to Share Buyback Plan	04/06	MT
Amphastar Pharmaceuticals, Inc. announces an Increase in Equity Buyback.	03/06	CI
Sector Update: Health Care Stocks Slightly Higher Late Afternoon	23/05	MT
Sector Update: Health Care Stocks Advance Wednesday Afternoon	22/05	MT
Amphastar Pharmaceuticals Gains US FDA Approval for Generic Bronchospasm Drug	22/05	MT
Amphastar Pharmaceuticals, Inc. Receives FDA Approval for Albuterol Sulfate Inhalation Aerosol	22/05	CI
Tranche Update on Amphastar Pharmaceuticals, Inc.'s Equity Buyback Plan announced on November 8, 2016.	10/05	CI
Amphastar Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	09/05	CI
Earnings Flash (AMPH) AMPHASTAR PHARMACEUTICALS Reports Q1 EPS $1.04, vs. Street Est of $0.79	09/05	MT
Earnings Flash (AMPH) AMPHASTAR PHARMACEUTICALS Reports Q1 Revenue $171.8M, vs. Street Est of $174.7M	09/05	MT
FTC Challenging 'Junk' Patent Listings for Ozempic, Victoza, Other Medications	01/05	MT
Top Midday Stories: Shares of Eli Lilly, HSBC Get Post-Earnings Bump; BBVA Exploring Merger With Sabadell; FTC Disputes 300 'Junk' Patent Listings	30/04	MT
FTC Challenging 'Junk' Patent Listings for Ozempic, Victoza, Other Medications	30/04	MT
FTC Challenging 'Junk' Patent Listings for Ozempic, Victoza, Other Medications	30/04	MT
FTC Challenging 'Junk' Patent Listings for Ozempic, Victoza, Other Medications	30/04	MT
Tranche Update on Amphastar Pharmaceuticals, Inc.'s Equity Buyback Plan announced on November 8, 2016.	01/03	CI
Amphastar Pharmaceuticals Q4 Adjusted Earnings, Revenue Rise	29/02	MT
Amphastar Pharmaceuticals, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023	29/02	CI
Earnings Flash (AMPH) AMPHASTAR PHARMACEUTICALS Posts Q4 EPS $0.88, vs. Street Est of $0.91	29/02	MT
Earnings Flash (AMPH) AMPHASTAR PHARMACEUTICALS Reports Q4 Revenue $178.1M, vs. Street Est of $173.3M	29/02	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Amphastar Pharmaceuticals, Inc.

Equities

AMPH

US03209R1032

Highlights

Filters